Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank50
3Y CAGR-15.4%
5Y CAGR-26.4%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-15.4%/yr
Annual compound
5Y CAGR
-26.4%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2024 | 2.44 | - |
| 2023 | 0.00 | -100.0% |
| 2022 | 50.94 | +1165.1% |
| 2021 | 4.03 | -89.0% |
| 2020 | 36.75 | +226.0% |
| 2019 | 11.27 | - |
| 2018 | 0.00 | - |
| 2017 | 0.00 | - |
| 2016 | 0.00 | - |